scholarly journals Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl

2017 ◽  
Vol 9 (2) ◽  
pp. 332-340 ◽  
Author(s):  
Yutaka Seino ◽  
Daisuke Yabe ◽  
Takashi Sasaki ◽  
Atsushi Fukatsu ◽  
Hisae Imazeki ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Fat Mass ◽  
Receptor Agonist ◽  
Japanese Patients ◽  
Open Label ◽  
Sodium Glucose Cotransporter ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment

2020 ◽  
Vol 17 (6) ◽  
pp. 147916412097122
Author(s):  
Takeyuki Hiramatsu ◽  
Hiroki Ito ◽  
Shota Okumura ◽  
Yuko Asano ◽  
Daiki Iguchi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Renal Function ◽  
Renal Impairment ◽  
Cardiac Function ◽  
Receptor Agonist ◽  
Sodium Glucose Cotransporter ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Introduction: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. Materials and methods: A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1): n = 72 or Group S (SGLT-2 inhibitor)—dapagliflozin ( n = 52) or empagliflozin ( n = 32). Renal function was assessed every 3 months for 36 months. Cardiovascular parameters were evaluated every 12 months for 36 months. Results: Compared with baseline, HbA1c and systolic blood pressure significantly decreased in both groups ( p < 0.05). The estimated glomerular filtration rate decreased, but without significance. Albuminuria decreased significantly in both groups and then subsequently increased after 30 months in Group S. Diastolic cardiac function, assessed by E/e′ or left atrial volume index, decreased only in Group G at 36 months. Conclusions: The GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months.

scholarly journals A practical Guide to Treatment with Liraglutide

2010 ◽  
Vol 2 ◽  
pp. CMT.S4148 ◽  
Author(s):  
Devasenan Devendra ◽  
Vassiliki Bravis
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Weight ◽  
Glycemic Control ◽  
Receptor Agonist ◽  
Efficacy And Safety ◽  
Once Daily ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Liraglutide–-a once-daily human glucagon-like peptide-1 receptor agonist for treatment of Type 2 diabetes–-provides effective glycemic control with a lower incidence of hypoglycemia than therapies such as glimepiride and exenatide, and reduces body weight and systolic blood pressure. This article briefly discusses efficacy and safety results from the Liraglutide Effect and Action in Diabetes (LEAD) program, before considering practical issues of identifying and educating patients who may be suitable for liraglutide therapy.

Sign in / Sign up

Export Citation Format

Share Document